Vision and Mission Healthcare Statements Peer Reviewed Articles

NASHVILLE, Tenn.--(BUSINESS WIRE)-- Harrow Wellness, Inc. (Nasdaq: HROW), an ophthalmic-focused healthcare company, today announced the appointments of Perry J. Sternberg and Marty Makary, M.D., Thou.P.H. to the Visitor'southward Board of Directors, constructive immediately. The Company besides appear that Robert J. Kammer has resigned from Harrow Health's Lath of Directors, effective immediately. With these changes, Harrow Health's Lath will consist of six members.

"It is a pleasure to welcome Perry and Marty, two extraordinarily accomplished professionals, to the Harrow Wellness Board of Directors," said Mark L. Baum, Chairman and Main Executive Officer of Harrow Health. "Perry'due south repeated commercial success equally a senior executive at multiple leading eyecare companies, specifically his expertise in developing and implementing strategic marketing and tactical sales plans that drive acquirement growth of ophthalmic pharmaceuticals, will be of groovy value to Harrow equally we aggrandize our platform to include more than FDA‑canonical products, such equally AMP-100, which, if approved, we await to launch inside the next 12 months. Besides, Dr. Makary's all-encompassing experience as a surgeon, corporate advisor, and policy idea leader, and his research into vulnerable populations and access to healthcare, align with our mission to make medicines accessible and affordable for all Americans. We look forrad to the valuable perspectives, creative and strategic thinking, and strong governance that each will contribute as we continue to advance our twin goals of making Harrow Health a leading U.South. eyecare company and edifice value for Harrow's shareholders.

"I besides desire to thank Bob for his tremendous contributions – over the last decade – which helped make Harrow Health what it is today. As a founding shareholder of the Company, Bob was instrumental in raising our first round of financing, and he has been my partner ever since, serving on the Harrow Board and helping to chart our path forward – through many good times and, of form, through the challenges we faced while building our business organization. I am forever grateful for his guidance and support, and on behalf of the Harrow Wellness family, wish Bob only the very all-time in the future."

Perry Sternberg serves as President and Chief Executive Officer of Corium, Inc., a commercial-stage biopharmaceutical company leading the development and commercialization of novel central nervous system (CNS) therapies. Prior to joining Corium, he served as Executive Vice President and Head of U.S. Commercial for Shire Plc'southward ophthalmology business unit every bit well as 6 other Shire business units, which, during his tenure, in the aggregate, generated more than $viii billion in annual revenue. Sternberg too served every bit Chief Commercial Officeholder and Global Head of Shire'due south CNS Business organisation. Of notation, Sternberg was a leader on the squad responsible for Shire's 2013 acquisition of Xiidra™ as a development-stage drug candidate, which subsequently received FDA-approving, was commercialized under his leadership, and ultimately sold, in 2019, for more than than $5 billion. Sternberg previously served every bit Vice President and General Managing director, U.South. and Canada Pharmaceuticals at Bausch + Lomb, equally well every bit various leadership roles at Novartis Ophthalmics, Novartis Pharmaceuticals and Merck & Co., Inc. In his 25 years of feel in biotechnology and pharmaceuticals, Sternberg has had direct responsibility for launch and commercialization of more than than xx products across a wide range of therapeutic areas in diverse markets, including ophthalmic pharmaceuticals.

Marty Makary, M.D., M.P.H. is a healthcare expert and serves as Chief of Islet Transplant Surgery at Johns Hopkins. Makary is a frequent public policy skillful in the media and a leading voice for physicians, writing for The Wall Street Periodical. He is the author of two New York Times bestselling books on healthcare and has published over 250 scientific peer-reviewed manufactures, including articles on organizational civilization, surgical innovation, vulnerable populations, and the re-design of healthcare delivery. Makary has served in leadership at the Globe Health Organization and has been elected to the National Academy of Medicine. Makary has been a visiting professor at over 25 medical schools and is the recipient of the Nobility in Scientific discipline Award from the National Pancreas Foundation. Makary speaks oftentimes on the time to come of healthcare and what it ways for everyday Americans, business concern leaders, and healthcare professionals. His current research focuses on the appropriateness of medical intendance and the touch of the healthcare toll crunch on low-income populations. His newest volume, The Price We Pay, tells the stories of healthcare'southward disruptive innovators and the new movement to restore medicine to its mission.

Near Harrow Wellness

Harrow Health, Inc. (NASDAQ: HROW) is an ophthalmic-focused healthcare company. The Company owns and operates ImprimisRx, one of the nation's leading ophthalmology-focused pharmaceutical businesses, and Visionology, a direct-to-consumer center care subsidiary focused on chronic vision care. Harrow Health likewise holds non-controlling equity positions in Eton Pharmaceuticals, Surface Ophthalmics and Cook Pharmaceuticals, all of which started every bit Harrow Health subsidiaries, and owns royalty rights in four clinical-stage drug candidates being developed past Surface Ophthalmics and Melt Pharmaceuticals. For more information virtually Harrow Health, please visit the Investors section of the corporate website, harrowinc.com.

Forward-Looking Statements

This press release contains "forrard-looking statements" within the meaning of the U.S. Private Securities Litigation Reform Act of 1995. Any statements in this release that are not historical facts may be considered such "frontwards-looking statements." Frontwards-looking statements are based on management'due south electric current expectations and are discipline to risks and uncertainties which may cause results to differ materially and adversely from the statements independent herein. Some of the potential risks and uncertainties that could cause actual results to differ from those predicted include the continued impact of the COVID-nineteen pandemic and any future wellness epidemics on our financial status, liquidity and results of operations; our ability to brand commercially available our FDA‑canonical products and compounded formulations and technologies in a timely manner or at all; market acceptance of the Visitor'due south products and challenges related to the marketing of the Company'southward products; risks related to our pharmacy operations; our ability to enter into other strategic alliances, including arrangements with pharmacies, physicians and healthcare organizations for the development and distribution of our products; our ability to obtain intellectual belongings protection for our assets; our power to accurately estimate our expenses and cash burn, and enhance additional funds when necessary; risks related to research and development activities; the projected size of the potential market for our technologies and products; unexpected new data, safe and technical problems; regulatory and market developments impacting compounding pharmacies, outsourcing facilities and the pharmaceutical industry; competition; and market weather condition. These and boosted risks and uncertainties are more fully described in Harrow Health's filings with the Securities and Exchange Commission, including its Annual Study on Class 10-Thou and its Quarterly Reports on Form ten-Q. Such documents may exist read complimentary of charge on the SEC's spider web site at www.sec.gov. Undue reliance should non be placed on forwards-looking statements, which speak but equally of the date they are fabricated. Except every bit required by law, Harrow Wellness undertakes no obligation to update any forward-looking statements to reflect new information, events or circumstances after the date they are made, or to reflect the occurrence of unanticipated events.

View source version on businesswire.com: https://world wide web.businesswire.com/news/dwelling/20220331005238/en/

wentworthcarposept.blogspot.com

Source: https://www.biospace.com/article/releases/harrow-health-announces-appointments-to-its-board-of-directors/

Share this post